Clarius Mobile Health Gets FDA Nod for AI Ultrasound Musculoskeletal Imaging Model
In what is reportedly the first Food and Drug Administration (FDA) 510(k) clearance for the use of artificial intelligence (AI) for musculoskeletal ultrasound, the model provides automated measurements of tendons in the knee, ankle, and foot.
Offering real-time identification and automated tendon measurements of the patellar tendon, plantar fascia and Achilles tendon, a new artificial intelligence (AI)-powered musculoskeletal ultrasound imaging application has received 510(k) clearance from the Food and Drug Administration (FDA).
Clarius Mobile Health said the AI model identifies viewed tendons with a transparent color overlay, labels the tendon and provides subsequent measurement calipers that align with the bottom and top of the tendon at its thickest region. Users of the AI musculoskeletal ultrasound application can then adjust the measurements to facilitate clinical decision-making, according to the company.
Alan Hirahara, M.D., says the new AI musculoskeletal application is “ground-breaking technology” that will assist new ultrasound users in learning musculoskeletal structures and enhance efficiency for radiologist assessment of musculoskeletal structures.
“The technology will … help current users standardize how structures are measured. In research, interobserver variability exists for any measurement of structures. With the AI standardization of measurements, interobserver reliability problems will now be non-existent. I am excited to see where this technology will go … ,” noted Dr. Hirahara, an orthopedic surgeon in private practice in Sacramento, Calif.
Clarius Mobile Health said the musculoskeletal AI model will soon be available through its Clarius L7 HD3 and Clarius L15 HD3 handheld ultrasound scanners.
(Editor’s note: For related content, see “Pie Medical Imaging Launches AI-Powered Echocardiography Platform” and “Samsung Gets FDA Nod for Versatile V7 Ultrasound System.”)
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
